ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer

Camizestrant (AstraZeneca), used in combination with a CDK4/6 inhibitor, resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when used as a first-line treatment in patients with ESR1-mutated hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. These findings, which were presented at the 2025 American Society of Clinical Oncology in Chicago, Illinois, represent a potential new treatment strategy to improve and optimize patient outcomes in the first-line setting.¹